Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Penumbra Inc (PEN)

Penumbra Inc (PEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,896,626
  • Shares Outstanding, K 34,914
  • Annual Sales, $ 444,940 K
  • Annual Income, $ 6,600 K
  • 60-Month Beta 0.73
  • Price/Sales 12.18
  • Price/Cash Flow 225.82
  • Price/Book 11.99

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.18
  • Number of Estimates 3
  • High Estimate 0.22
  • Low Estimate 0.13
  • Prior Year 0.13
  • Growth Rate Est. (year over year) +38.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
155.45 +9.74%
on 01/09/20
172.12 -0.89%
on 01/22/20
+10.91 (+6.83%)
since 12/20/19
3-Month
148.58 +14.81%
on 10/23/19
178.74 -4.56%
on 11/29/19
+20.59 (+13.73%)
since 10/22/19
52-Week
122.40 +39.37%
on 04/17/19
185.70 -8.14%
on 07/25/19
+29.86 (+21.22%)
since 01/22/19

Most Recent Stories

More News
Penumbra Announces FDA Clearance of Indigo(R) Aspiration System for Treatment of Pulmonary Embolism

Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced U.S. Food and Drug Administration 510(k) clearance for expanded indication of the Indigo(R) Aspiration...

PEN : 170.59 (+1.01%)
Penumbra, Inc. to Present at the 38th Annual J.P. Morgan Healthcare Conference

Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 14, 2020.

JPM : 136.68 (-0.12%)
PEN : 170.59 (+1.01%)
Maggie Yuen Appointed Chief Financial Officer Of Penumbra

Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced the appointment of Maggie Yuen as CFO of Penumbra, effective December 2, 2019.

PEN : 170.59 (+1.01%)
TMO : 340.05 (+0.83%)
Penumbra, Inc. Announces Investor Day 2019

Penumbra, Inc. (NYSE: PEN) today announced that it will host an Investor Day on Tuesday, December 3, 2019 in Boston, MA at 8:30am Eastern Time.

PEN : 170.59 (+1.01%)
Penumbra's (PEN) Q3 Earnings & Revenues Surpass Estimates

Penumbra (PEN) witnessed strong growth across all geographies and product lines in Q3.

TMO : 340.05 (+0.83%)
PEN : 170.59 (+1.01%)
EW : 242.99 (+0.36%)
RMD : 164.38 (+1.51%)
Penumbra (PEN) Beats Q3 Earnings and Revenue Estimates

Penumbra (PEN) delivered earnings and revenue surprises of 38.89% and 4.59%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

PEN : 170.59 (+1.01%)
Penumbra: 3Q Earnings Snapshot

ALAMEDA, Calif. (AP) _ Penumbra Inc. (PEN) on Thursday reported third-quarter net income of $11.5 million, after reporting a loss in the same period a year earlier.

PEN : 170.59 (+1.01%)
Penumbra, Inc. Reports Third Quarter 2019 Financial Results

Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the third quarter ended September 30, 2019.

PEN : 170.59 (+1.01%)
Penumbra Indigo(R) Aspiration System IDE Trial for Acute Pulmonary Embolism Meets Primary Safety and Efficacy Endpoints

Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced that the EXTRACT-PE trial successfully met the primary endpoints, demonstrating the safety and efficacy...

PEN : 170.59 (+1.01%)
Medical Products' Nov 7 Earnings Roster: ABC, CAH & More

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.

ABT : 91.86 (+2.37%)
VAR : 149.57 (+1.01%)
PEN : 170.59 (+1.01%)
XRAY : 60.71 (+0.61%)
ABC : 92.03 (+0.85%)
CAH : 55.32 (+2.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade PEN with:

Business Summary

Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company's portfolio of products primarily addresses neuro and peripheral vascular medical conditions and clinical needs. Neuro products include Neurovascular Access, Neuron Access...

See More

Key Turning Points

2nd Resistance Point 173.56
1st Resistance Point 172.08
Last Price 170.59
1st Support Level 169.15
2nd Support Level 167.70

See More

52-Week High 185.70
Last Price 170.59
Fibonacci 61.8% 161.52
Fibonacci 50% 154.05
Fibonacci 38.2% 146.58
52-Week Low 122.40

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar